Results 271 to 280 of about 1,468,899 (328)

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

open access: yesMolecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller   +17 more
wiley   +1 more source

Wearing Regulation Soft-Padded Headgear Does Not Reduce the Risk of Head Injuries in Professional Men's Rugby Players: An Observational Cohort Study. [PDF]

open access: yesEur J Sport Sci
Brown J   +12 more
europepmc   +1 more source

Early Adoption of Services for Health-Related Social Needs in Medicare.

open access: yesJAMA Health Forum
Billig JI   +6 more
europepmc   +1 more source

Sleep duration promotes resistance and resilience to tau in older women at risk for Alzheimer's disease. [PDF]

open access: yesAlzheimers Dement
Stiver J   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy